Ontology highlight
ABSTRACT: Background
Glioblastoma (GBM) is an incurable disease with few approved therapeutic interventions. Radiation therapy (RT) and temozolomide (TMZ) remain the standards of care. The efficacy and optimal deployment schedule of the orally bioavailable small-molecule tumor checkpoint controller lisavanbulin alone, and in combination with, standards of care were assessed using a panel of IDH-wildtype GBM patient-derived xenografts.Methods
Mice bearing intracranial tumors received lisavanbulin +/-RT +/-TMZ and followed for survival. Lisavanbulin concentrations in plasma and brain were determined by liquid chromatography with tandem mass spectrometry, while flow cytometry was used for cell cycle analysis.Results
Lisavanbulin monotherapy showed significant benefit (P < .01) i
SUBMITTER: Burgenske DM
PROVIDER: S-EPMC8917401 | biostudies-literature | 2022 Mar
REPOSITORIES: biostudies-literature